Global Oxidative Stress Assay Market Size study & Forecast, by Product (Instruments, Consumables, Services) by Test Type (Indirect Assays, Antioxidant Capacity Assays, Enzyme-Based Assays, Reactive Oxygen Species-Based Assays) by Technology, by Disease Ty

Global Oxidative Stress Assay Market Size study & Forecast, by Product (Instruments, Consumables, Services) by Test Type (Indirect Assays, Antioxidant Capacity Assays, Enzyme-Based Assays, Reactive Oxygen Species-Based Assays) by Technology, by Disease Type, by End-user and Regional Analysis, 2023-2030.

Global Oxidative Stress Assay Market is valued approximately at USD 1.12 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 9.45% over the forecast period 2023-2030. Oxidative stress assay is a method used to measure the levels of reactive oxygen species (ROS) or the ability of antioxidants to neutralize ROS in cells or tissues. Oxidative stress occurs when there is an imbalance between the production of ROS and the ability of the body to counteract their harmful effects through antioxidants. This imbalance can lead to damage to proteins, lipids, and DNA, and is associated with various diseases including cancer, cardiovascular diseases, and neurodegenerative disorders.

The rising frequency of oxidative stress-related illnesses, the rise in pharmaceutical companies' and academic institutions' R&D endeavoursendeavors, and the development of oxidative stress assays through technology are all expected to contribute to the market's expected significant growth in the upcoming years. Furthermore, positive efforts by major players and governmental organisations to lower the global disease burden are expected to stimulate research, raising the need for oxidative stress assays worldwide. It is anticipated that the market will expand more due to the rising prevalence of oxidative stress-related diseases such diabetes, cancer, respiratory disorders, and cardiovascular disorders. A study released in April 2023 by the Institute for Health Metrics and Evaluation estimates that there are around 454.6 million instances of chronic respiratory disorders worldwide, including asthma, pneumoconiosis, COPD, and others. Furthermore, six out of ten Americans who suffer from a chronic illness—such as cancer, diabetes, COPD, chronic renal disease, cardiovascular disease, and others—also have oxidative stress as a contributing factor. The need for oxidative stress tests is predicted to rise globally due to an increased risk of developing certain chronic health disorders. Given that oxidative stress is linked to a number of chronic diseases, it is anticipated that the need for oxidative stress tests would rise in tandem with pharmaceutical and biotechnology companies' increasing R&D spending to create novel treatments for various life-threatening disorders. The Pharma R&D Annual Review, which was released in June 2023, states that there were around 21,292 pharmaceutical drugs in research phases worldwide and 5,529 pharmaceutical businesses engaged in R&D. About 17.5% of all pharmaceutical pipeline medications are produced by small-to-midsized pharmaceutical and research enterprises. Furthermore, the European pharmaceutical industry spent around USD 48 billion on research and development efforts in 2021, according to the EFPIA 2023 report. It is anticipated that rising R&D costs to create innovative therapeutic medications for specific illnesses will boost oxidative stress's commercial acceptance. However, the hHigh cCost of iInstruments stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Oxidative Stress Assay Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. In 2022, North America accounted dominated the market withfor the largest share of the global market for oxidative stress assays. The development of innovative treatments for various diseases and improved healthcare infrastructure, along with the presence of several pharmaceutical and biopharmaceutical businesses and research centrescenters, are driving the expansion of the regional market. Due to significant R&D expenditures and supportive government measures to encourage R&D operations in the healthcare industry, the U.S. market held the highest share in 2023. In 2020, the United States spent over USD 245 billion on medical and health research and development, and this amount is projected to rise in the years to come. Asia Pacific is anticipated to grow at the fastest CAGR since rising nations like China and India are predicted to produce significant amounts of revenue in 2022. Furthermore, throughout the course of the forecast period, rising healthcare spending generally and a sharp increase in R&D spending by pharmaceutical companies and government-funded research institutes are expected to propel regional market expansion.

Major market player included in this report are:
Abcam Limited
AMS Biotechnology (AMSBIO)AMSBIO
Cell Biolabs, Inc.
Enzo Life Sciences, Inc.
Merck KGaA
ImmunoChemistry Technologies
Promega Corporation
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Oxford Biomedical Research

Recent Developments in the Market:
 In February 2022, Invitae declared that its LiquidPlex Dx and FusionPlex Dx for precision oncology diagnostics are now available in European nations.
 In July 2021, Immuchrom GmbH, which specialises in oxidative stress, cardiovascular disease, and other gastrointestinal disorders, partnered with Ilex Life Sciences LLC to distribute gastrointestinal biomarker assays throughout the North American continent.

Global Oxidative Stress Assay Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product, Test Type, Technology, Disease Type, End User, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Instruments
Consumables
Services

By Test Type:
Indirect Assays
Antioxidant Capacity Assays
Enzyme-Based Assays
Reactive Oxygen Species-Based Assays

By Technology:
Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Chromatography
Microscopy
Others

By Disease Type:
Cardiovascular disease
Respiratory Diseases
Cancer
Diabetes
Others

By End-user:
Pharmaceutical and Biotechnology Industries
Academic Research institutes
Contract Research Organizations
Clinical Laboratories
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.